Table 3.
The use of neoadjuvant systemic therapy by intrinsic subtype
Characteristic | HR−/HER2−, N = 35a | HR−/HER2+, N = 5a | HR+/HER2−, N = 397a | HR+/HER2+, N = 52a | Unknown, N = 11a | p-valueb |
---|---|---|---|---|---|---|
Neoadjuvant treatment administered | 26 (74.3%) | 3 (60.0%) | 101 (25.4%) | 32 (61.5%) | 3 (27.3%) | < 0.001 |
Neoadjuvant chemotherapy administered | 26 (74.3%) | 2 (40.0%) | 89 (22.4%) | 32 (61.5%) | 2 (18.2%) | < 0.001 |
an (%)
bFisher’s exact test
HR Hormonal receptors, HER2 Human epidermal growth factor receptor 2